These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22169601)

  • 1. Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.
    Beckers T; Sellmer A; Eichhorn E; Pongratz H; Schächtele C; Totzke F; Kelter G; Krumbach R; Fiebig HH; Böhmer FD; Mahboobi S
    Bioorg Med Chem; 2012 Jan; 20(1):125-36. PubMed ID: 22169601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
    Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD
    J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
    Cha MY; Lee KO; Kang SJ; Jung YH; Song JY; Choi KJ; Byun JY; Lee HJ; Lee GS; Park SB; Kim MS
    J Med Chem; 2012 Mar; 55(6):2846-57. PubMed ID: 22372864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
    Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
    Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
    J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syntheses and anti-cancer activities of 2-[1-(indol-3-yl-/pyrimidin-5-yl-/pyridine-2-yl-/quinolin-2-yl)-but-3-enylamino]-2-phenyl-ethanols.
    Singh P; Kaur P; Luxami V; Kaur S; Kumar S
    Bioorg Med Chem; 2007 Mar; 15(6):2386-95. PubMed ID: 17275313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold.
    Chilin A; Conconi MT; Marzaro G; Guiotto A; Urbani L; Tonus F; Parnigotto P
    J Med Chem; 2010 Feb; 53(4):1862-6. PubMed ID: 20095624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
    Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, antimicrobial, anticancer evaluation and QSAR studies of 6-methyl-4-[1-(2-substituted-phenylamino-acetyl)-1H-indol-3-yl]-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl esters.
    Sharma SK; Kumar P; Narasimhan B; Ramasamy K; Mani V; Mishra RK; Majeed AB
    Eur J Med Chem; 2012 Feb; 48():16-25. PubMed ID: 22154835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90.
    Huang KH; Barta TE; Rice JW; Smith ED; Ommen AJ; Ma W; Veal JM; Fadden RP; Barabasz AF; Foley BE; Hughes PF; Hanson GJ; Markworth CJ; Silinski M; Partridge JM; Steed PM; Hall SE
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2550-4. PubMed ID: 22386527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.